StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU)

Mon, 24 Aug 2026 06:55:10 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $12.00 price target on AC Immune SA (NASDAQ: ACIU).

The analyst commented: "On August 20, ACI-19764 delivered the first of a two-part Phase 1 readout, in which we believe the CNS exposure data is the key data point to focus on. The company confirmed brain penetration via CSF exposure, with daily doses of ≤10mg exceeding the IC90 and blinded whole-blood assay data showing dose-dependent IL-1β inhibition. That said, the number we would like to see is CSF IC90 coverage, because it is brain exposure that determines whether the central target is

AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764

Thu, 20 Aug 2026 07:00:16 -0400

AC Immune SA (NASDAQ: ACIU) announced preliminary results from a Phase 1 first-in-human clinical study of ACI-19764, an oral small molecule inhibitor of the NLRP3 inflammasome, according to a company statement.

The study, conducted in healthy volunteers in Europe, evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics across single ascending dose and multiple ascending dose cohorts. ACI-19764 was reported as safe and well-tolerated at doses up to 20mg per day, with a serum half-life greater than 30 hours. No serious adverse events or treatment withdrawals were recorded. Cerebrospinal fluid exposure confirmed brain penetration of the compound.

Pharmacokinetic data indicated that daily doses of 10mg

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

Thu, 20 Aug 2026 07:00:00 -0400

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome
Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration
Based on PK data the therapeutic dose is expected to be ≤10mg once daily
To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end
Full results from the Phase 1/1b trial are expected in H1 2027

Lausanne,

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

Thu, 20 Aug 2026 07:00:00 -0400

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome
Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration
Based on PK data the therapeutic dose is expected to be ≤10mg once daily
To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end
Full results from the Phase 1/1b trial are expected in H1 2027

Lausanne,

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

Thu, 20 Aug 2026 07:00:00 -0400

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome
Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration
Based on PK data the therapeutic dose is expected to be ≤10mg once daily
To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end
Full results from the Phase 1/1b trial are expected in H1 2027

Lausanne,

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

Thu, 20 Aug 2026 07:00:00 -0400

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome
Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration
Based on PK data the therapeutic dose is expected to be ≤10mg once daily
To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end
Full results from the Phase 1/1b trial are expected in H1 2027

Lausanne,

Form 6-K AC Immune SA For: Aug 20

Thu, 20 Aug 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260820/26952622.html

Form 6-K AC Immune SA For: Aug 20

Thu, 20 Aug 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260820/26952622.html

AC Immune gets FDA fast track for Parkinson's drug ACI-7104

Tue, 11 Aug 2026 07:00:13 -0400

AC Immune SA (NASDAQ: ACIU) announced it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACI-7104, its anti-alpha-synuclein active immunotherapy candidate for early-stage Parkinson's disease, according to a company statement dated August 11, 2026.

The FDA also cleared the company's Investigational New Drug (IND) application for ACI-7104, allowing the ongoing Phase 2 VacSYn trial to expand to sites in the United States. The Lausanne, Switzerland-based company said full week-100 results from Part 1 of the VacSYn trial are expected in the second half of 2026.

ACI-7104 is designed to induce antibodies that preferentially recognize aggregated alpha-synuclein

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Tue, 11 Aug 2026 07:00:00 -0400

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance
Recent positive interim results showed safety and immunogenicity with early signals of activity
Full week-100 results from Part 1 of VacSYn trial expected in H2 2026

Lausanne, Switzerland, August 11, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced that it has received Fast Track designation and clearance of its

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Tue, 11 Aug 2026 07:00:00 -0400

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance
Recent positive interim results showed safety and immunogenicity with early signals of activity
Full week-100 results from Part 1 of VacSYn trial expected in H2 2026

Lausanne, Switzerland, August 11, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced that it has received Fast Track designation and clearance of its

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Tue, 11 Aug 2026 07:00:00 -0400

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance
Recent positive interim results showed safety and immunogenicity with early signals of activity
Full week-100 results from Part 1 of VacSYn trial expected in H2 2026

Lausanne, Switzerland, August 11, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced that it has received Fast Track designation and clearance of its

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Tue, 11 Aug 2026 07:00:00 -0400

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

Ongoing Phase 2 VacSYn study to expand to sites in USA with Investigational New Drug (IND) clearance
Recent positive interim results showed safety and immunogenicity with early signals of activity
Full week-100 results from Part 1 of VacSYn trial expected in H2 2026

Lausanne, Switzerland, August 11, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced that it has received Fast Track designation and clearance of its

Form 6-K AC Immune SA For: Aug 11

Tue, 11 Aug 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260811/26901120.html

Form 6-K AC Immune SA For: Aug 11

Tue, 11 Aug 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260811/26901120.html

Form 6-K AC Immune SA For: Jun 30

Wed, 05 Aug 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260805/26870041.html

Form 6-K AC Immune SA For: Jun 30

Wed, 05 Aug 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260805/26870041.html

AC Immune First Half 2026 Financial and Corporate Update

Wed, 05 Aug 2026 07:00:00 -0400

AC Immune First Half 2026 Financial and Corporate Update

Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments

Key advances across pipeline, with further near-term clinical results anticipated for H2 2026
Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation
Morphomer small molecule program targeting intracellular Tau progresses with Lilly
Initiation of Alzheimer’s disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda

Cash resources of CHF 75.4

AC Immune First Half 2026 Financial and Corporate Update

Wed, 05 Aug 2026 07:00:00 -0400

AC Immune First Half 2026 Financial and Corporate Update

Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments

Key advances across pipeline, with further near-term clinical results anticipated for H2 2026
Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation
Morphomer small molecule program targeting intracellular Tau progresses with Lilly
Initiation of Alzheimer’s disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda

Cash resources of CHF 75.4

AC Immune First Half 2026 Financial and Corporate Update

Wed, 05 Aug 2026 07:00:00 -0400

AC Immune First Half 2026 Financial and Corporate Update

Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments

Key advances across pipeline, with further near-term clinical results anticipated for H2 2026
Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation
Morphomer small molecule program targeting intracellular Tau progresses with Lilly
Initiation of Alzheimer’s disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda

Cash resources of CHF 75.4

AC Immune First Half 2026 Financial and Corporate Update

Wed, 05 Aug 2026 07:00:00 -0400

AC Immune First Half 2026 Financial and Corporate Update

Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments

Key advances across pipeline, with further near-term clinical results anticipated for H2 2026
Phase 2 VacSYn trial of ACI-7104 in Parkinson’s disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable Foundation
Morphomer small molecule program targeting intracellular Tau progresses with Lilly
Initiation of Alzheimer’s disease AD4 cohort in ABATE trial triggered $12 million milestone payment from Takeda

Cash resources of CHF 75.4

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

Tue, 07 Jul 2026 07:00:00 -0400

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC^® 2026

Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference^® 2026, taking place July 12-15 in London, UK.

Across these AAIC presentations, we are showing how AC Immune’s Morphomer^®-based small molecule approach has generated differentiated therapeutic and imaging assets. Our first-in-class TDP-43 PET tracer has generated encouraging early human imaging data in FTD and ALS; our novel brain-penetrant NLRP3 inhibitor is in Phase

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026

Tue, 07 Jul 2026 07:00:00 -0400

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC^® 2026

Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference^® 2026, taking place July 12-15 in London, UK.

Across these AAIC presentations, we are showing how AC Immune’s Morphomer^®-based small molecule approach has generated differentiated therapeutic and imaging assets. Our first-in-class TDP-43 PET tracer has generated encouraging early human imaging data in FTD and ALS; our novel brain-penetrant NLRP3 inhibitor is in Phase

H.C. Wainwright Reiterates Buy Rating on AC Immune SA (ACIU)

Wed, 01 Jul 2026 07:04:43 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $12.00 price target on AC Immune SA (NASDAQ: ACIU).
The analyst commented: "Yesterday, AC Immune reported interim 12-month data from the first three ABATE cohorts (AD1, AD2, AD3; n=74 prodromal AD patients). Key takeaways from the readout are as follows. First, ACI-24 was generally safe and well tolerated with no ARIA-E across any dose cohort. Second, anti-Abeta antibody responses were detected at every dose level with a dose-response relationship confirmed meaning that the immunotherapy engages the immune system as designed across the tested range. Third, AD4 is now testing ACI-24 with

Form 6-K AC Immune SA For: Jun 30

Tue, 30 Jun 2026 09:03:00 -0400
si-local-file:///var/storage/secattach/20260630/26710764.html